Therapeutic Area: Oncology

Disease State:
Solid Tumors (Lung, Breast & Ovarian)

Educational Objectives

Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations to optimize therapeutic strategies.
1. Improve clinicians’ and pathologists’ knowledge of gene mutations and the utility of biomarker analysis in targeted treatment approaches to improve patient outcomes.
Describe mechanisms for resistance to inhibition of molecular signaling pathways and the durability of response of approved and investigational pathway inhibitors.
Enhance clinicians’ knowledge of signaling pathways in the development and progression of NSCLC and the consequences of deregulation.
Improve clinicians’ understanding of the continuation of treatment in later lines of therapy.
Increase clinicians’ knowledge and appropriate application of evidence-based clinical data in selection of therapeutic options for the management of solid tumors (including NSCLC, breast cancer, and ovarian cancer)
1. Understand how safety and tolerability of treatment may impact patient outcomes.
Increase the awareness among patients, allied and clinical healthcare providers of the global burden of lung cancer, risks/benefits of treatment, strategic approaches to personalized care, and expanding therapeutic options.
Enhance clinicians’ understanding of the roles of proangiogenic signaling pathways in the development and progression of NSCLC.

Describe the impact of interactions between growth factors and their receptors on cellular proliferation, migration, differentiation, and cellular survival.

Improve clinicians’ knowledge of research discussing clinical outcomes in advanced/metastatic NSCLC when inhibiting multiple proangiogenic signaling pathways.

Improve clinicians’ awareness of data discussing antiangiogenic therapies for NSCLC in combination with standard chemotherapy.